Please Wait...

Lost to Follow-Up

Finding Patients Lost to Follow-Up

The ultimate success of any clinical trial depends upon the timely submission of complete and accurate data. When study subjects drop out of your trial, it compromises your data's integrity. Plus, it costs you money and delays your clinical trial endpoint.

Bioclinica's lost to follow-up service, Bioclinica L2FU®, optimizes clinical trial success by greatly reducing the number of patients lost to follow-up and, with them, important data. We locate lost to follow-up clinical trial patients in more than 60 countries worldwide, with the support of a specialized team and a secure online portal to facilitate the encrypted exchange of patient information.

Why Choose Bioclinica L2FU®?

  • Provide vital status on subjects
  • Maintain clinical trial integrity by reducing missing data
  • Comply with FDA, EMEA, and regulatory guidelines or requests
  • Enable a faster clinical trial endpoint
  • Reduce clinical trial costs
  • Comply with GCP guidelines related to information security
  • Maintain full HIPAA compliance for data privacy

ADDITIONAL RESOURCES

Patient Recruitment and Retention

Download Brochure

Alzheimer's Disease

Download Case Study

Pediatric Schizophrenia

Download Case Study

Chronic Pain Study

Download Case Study

RAPSODI Study

Download Case Study

ALLEGRO Study

Download Case Study

The ALFACHIN Study

Download Case Study

Childhood Depression Study

Download Case Study

Nerve Pain Study

Download Case Study

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @lauren_chazal: OA is highly prevalent worldwide! Let's work together globally to fight OA... #orasi2017 @bioclinica https://t.co/sAofL…
bioclinica (2 days ago)
Awesome #TYCTWD in our Audubon office yesterday! Great grp of kids.Thanks all for making it a big hit & a day to r… https://t.co/gLZilvN4Wy
bioclinica (2 days ago)
[Fun Friday] When It Comes to Success, Age Really Is Just a Number Via NYT https://t.co/u82mvoYxhg
bioclinica (2 days ago)
RT @eClinical_Jen: Ron Fitzmartin of FDA states "The Reason why the FDA supports standards is to get medical products approved faster" 👍#C…
bioclinica (3 days ago)
RT @eClinical_Jen: Donate your health data to research! Check out the S4S project mentioned by @iamnotthelotus at #CDISCEurope #pharma http…
bioclinica (3 days ago)
RT @lauren_chazal: #oarsi2017 what IS the future of OA? @bioclinica https://t.co/Q9MhW8F50g
bioclinica (3 days ago)

Latest Blogs: